HLX12 (ramucirumab biosimilar) / Fosun Pharma - LARVOL DELTA

Compare Pharmacokinetic, Safety, Tolerability and Immunogenicity of HLX12 and Ramucirumab in Healthy Male Adult Subjects (clinicaltrials.gov) - P1 | N=24 | Terminated | Sponsor: Shanghai Henlius Biotech | N=152 ➔ 24 | Recruiting ➔ Terminated; The study was terminated prematurely due to the difficulty in recruiting participants caused by the COVID-19 pandemic.

Enrollment change • Trial termination